Efficacy of sustained release morphine and immediate release morphine for treatment of cancer pain a comparative study

The efficacy of sustained release morphine and instant release morphine for treatment of cancer pain :A comparative study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/01/039252

Enrollment

Registered

2022-01-07

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: Efficacy of sustained release morphine tablet: Group S patient will recieve Sustained release morphine tablet total dose 30 mg (10 mg TDS),ORAL Control Intervention1: Efficacy of immedi

Eligibility

Inclusion criteria

Inclusion criteria: 1. Analgesics regimen >60mg/day of orally given morphine 2. Life expectancy 3. written informed consent

Exclusion criteria

Exclusion criteria: 1. Patient refusal for consent. 2. Chemotherapy or radiotherapy that didnâ??t allow accurate dose titration of morphine 3. Impaired bowel mobility or intractable vomiting 4. Inability to swallow whole capsule 5. History of respiratory depression 6. History of allergy to proposed/used drugs in the study 7. Patients with multiple organ failure 8. Inability to comply with protocol.

Design outcomes

Primary

Measure	Time frame
To compare VAS scores of two groupsTimepoint: 2 weeks	—

Secondary

Measure	Time frame
To compare patient complianceTimepoint: 7 days	—

Countries

India

Contacts

Public ContactUrmila Palaria

Government medical college, Haldwani

urmila_palaria@rediffmail.com9897088443

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026